A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors

Study Status

Closed to Enrollment

Study Description

The purpose of this study is to assess the safety and determine the maximum tolerated dose of the combination of BSI-201 with chemotherapeutic regimens in patients with advanced solid tumors.

Patients will receive Gemcitabine via i.v. infusion once weekly for 3 weeks out of 4 and BSI-201 twice weekly for the first 3 weeks of a 4 week cycle.  Safety and efficacy assessments and procedures include physical exams and laboratory safety assessments, radiographic tumor response (CT/MRI scans), and exploratory testing.

Disease Status and/or Stage

Metastatic Pancreatic Cancer


BiPar Sciences

Key Eligibility

  • Men and women age 18 and older
  • Diagnosed with pancreatic cancer, whose disease has spread to other areas of the body
  • Additional eligibility criteria discussed when you contact the study team

Principal Investigator

Allyson Ocean, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page